Launois R, Le Moine JG, Huynh MT, Boissier MC. Analyse de l'impact budgétaire de la prise en charge de la polyarthrite rhumatoïde en 1ère, 2ème et 3ème ligne de traitement, après échec d'un traitement de fond. Presented at the French Society of Rheumatology 24th Annual Congress; December 11, 2011. Paris, France.
Wilburn J, McKenna S, Crawford SR, Perry-Hinsley D, Bayat A. Determining the true impact of dupuytren's disease: a qualitative study. Poster presented at the 2011 ISPOR 14th Annual European Congress; November 2011. Madrid, Spain. [abstract] Value Health. 2011 Nov; 14(7):A314-5.
Hollis K, Calingaert B, Gilligan TM, Sweeney C, Price M, Perez-Gutthann S, Andrews E. Quinolones REMS evaluation surveys. Poster presented at the 27th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 18, 2011. Chicago, IL.
Hauber AB, Fleischmann J, Lothgren M, Wilson M, Lam A, Dubois D, Sabatowski R. Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective. J Opioid Manag. 2011 Jul 1;7(4):287-96.
Primatesta P, Plana Hortoneda E, Rothenbacher D. Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population. BMC Musculoskelet Disord. 2011 May 20;12:103. doi: 10.1186/1471-2474-12-103